{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:30:44Z","timestamp":1778754644792,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271978"],"award-info":[{"award-number":["82271978"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92359304"],"award-info":[{"award-number":["92359304"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82330060"],"award-info":[{"award-number":["82330060"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejradiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Radiology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ejrad.2025.112057","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T20:32:49Z","timestamp":1742329969000},"page":"112057","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A nationwide investigation on imaging follow-up after Locoregional therapy for hepatocellular carcinoma in China: Current practices and challenges"],"prefix":"10.1016","volume":"186","author":[{"given":"Shuwei","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenxin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenghong","family":"Ju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6253-8311","authenticated-orcid":false,"given":"Yuan-Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejrad.2025.112057_b0005","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00330-022-08977-z","article-title":"Optimal imaging criteria and modality to determine Milan criteria for the prediction of post-transplant HCC recurrence after locoregional treatment","volume":"33","author":"Seo","year":"2023","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ejrad.2025.112057_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2024.111619","article-title":"Therapeutic analysis of 632 cases treated by transcatheter arterial chemoembolization combined with ablation in hepatocellular carcinoma: A retrospective study","volume":"178","author":"Jing","year":"2024","journal-title":"Eur J Radiol"},{"issue":"3","key":"10.1016\/j.ejrad.2025.112057_b0015","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.222776","article-title":"Per-patient Negative Predictive Value of the CT and MRI Liver Imaging Reporting and Data System Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma","volume":"309","author":"Hassan","year":"2023","journal-title":"Radiology"},{"key":"10.1016\/j.ejrad.2025.112057_b0020","first-page":"S619","article-title":"Comparison of quantitative response assessment criteria and LI-RADS treatment response algorithm in patients with hepatocellular carcinoma receiving locoregional therapies","volume":"45","author":"Schmidt","year":"2022","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"10.1016\/j.ejrad.2025.112057_b0025","year":"2024","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.ejrad.2025.112057_b0030","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.ejrad.2025.112057_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.engmed.2024.100037","article-title":"Transarterial chemoembolization for hepatocellular carcinoma: Treatment algorithm proposed by Chinese College of Interventionalists (CCI)","volume":"1","author":"Zhu","year":"2024","journal-title":"EngMedicine"},{"issue":"3","key":"10.1016\/j.ejrad.2025.112057_b0040","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3350\/cmh.2023.0202","article-title":"Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association","volume":"29","author":"Cho","year":"2023","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"10.1016\/j.ejrad.2025.112057_b0045","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-070364","article-title":"Diagnostic values of contrast-enhanced MRI and contrast-enhanced CT for evaluating the response of hepatocellular carcinoma after transarterial chemoembolisation: a meta-analysis","volume":"14","author":"Zhang","year":"2024","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.ejrad.2025.112057_b0050","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.231501","article-title":"LI-RADS CT and MRI Ancillary Feature Association with Hepatocellular Carcinoma and Malignancy: An Individual Participant Data Meta-Analysis","volume":"310","author":"Dawit","year":"2024","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.ejrad.2025.112057_b0055","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.ejrad.2025.112057_b0060","unstructured":"American College of Radiology. Liver imaging reporting and data system (LI-RADS). American College of Radiology Web site. https:\/\/www.acr.org\/-\/media\/ACR\/Files\/RADS\/LI-RADS\/LI-RADS-CTMR-Nonradiation-TRA-v2024-Core.pdf 2024."},{"key":"10.1016\/j.ejrad.2025.112057_b0065","unstructured":"American College of Radiology. Liver imaging reporting and data system (LI-RADS). American College of Radiology Web site. https:\/\/www.acr.org\/-\/media\/ACR\/Files\/RADS\/LI-RADS\/LI-RADS-CTMR-Radiation-TRA-v2024-Core.pdf 2024."},{"issue":"1","key":"10.1016\/j.ejrad.2025.112057_b0070","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jhep.2018.02.008","article-title":"Hepatic arterial infusion of oxaliplatin plus fluorouracil\/leucovorin vs. sorafenib for advanced hepatocellular carcinoma","volume":"69","author":"Lyu","year":"2018","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.ejrad.2025.112057_b0075","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamaoncol.2024.1831","article-title":"Survival in Patients With Recurrent Intermediate-Stage Hepatocellular Carcinoma: Sorafenib Plus TACE vs TACE Alone Randomized Clinical Trial","volume":"10","author":"Fan","year":"2024","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.ejrad.2025.112057_b0080","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/CAD.0000000000000371","article-title":"Raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma","volume":"27","author":"Zhao","year":"2016","journal-title":"Anticancer Drugs"},{"issue":"3","key":"10.1016\/j.ejrad.2025.112057_b0085","first-page":"532","volume":"15","year":"2024","journal-title":"Med J PUMCH,"},{"key":"10.1016\/j.ejrad.2025.112057_b0090","doi-asserted-by":"crossref","unstructured":"2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol, 2022, 28(4): 583-705. Doi: 10.3350\/cmh.2022.0294.","DOI":"10.3350\/cmh.2022.0294"},{"issue":"3","key":"10.1016\/j.ejrad.2025.112057_b0095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000514174","article-title":"Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update","volume":"10","author":"Kudo","year":"2021","journal-title":"Liver Cancer"},{"issue":"12","key":"10.1016\/j.ejrad.2025.112057_b0100","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3348\/kjr.2024.0626","article-title":"Survey of Experts' Opinions on the Diagnosis and Management of Pancreatic Cystic Neoplasms","volume":"25","author":"Yoon","year":"2024","journal-title":"Korean J Radiol"},{"issue":"5","key":"10.1016\/j.ejrad.2025.112057_b0105","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1159\/000525500","article-title":"Conventional or Drug-Eluting Beads? Randomized Controlled Study of Chemoembolization for Hepatocellular Carcinoma: JIVROSG-1302","volume":"11","author":"Ikeda","year":"2022","journal-title":"Liver Cancer"},{"issue":"9","key":"10.1016\/j.ejrad.2025.112057_b0110","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1097\/JS9.0000000000001691","article-title":"Comparison of drug-eluting bead with conventional transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a randomized clinical trial","volume":"110","author":"Zhou","year":"2024","journal-title":"Int J Surg"},{"issue":"2","key":"10.1016\/j.ejrad.2025.112057_b0115","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","year":"2025","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.ejrad.2025.112057_b0120","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jvir.2008.09.034","article-title":"Radiologic monitoring of hepatocellular carcinoma tumor viability after transhepatic arterial chemoembolization: estimating the accuracy of contrast-enhanced cross-sectional imaging with histopathologic correlation","volume":"20","author":"Hunt","year":"2009","journal-title":"J Vasc Interv Radiol"},{"issue":"3","key":"10.1016\/j.ejrad.2025.112057_b0125","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1148\/radiol.2020192797","article-title":"Diagnostic Performance of LI-RADS Treatment Response Algorithm for Hepatocellular Carcinoma: Adding Ancillary Features to MRI Compared with Enhancement Patterns at CT and MRI","volume":"296","author":"Park","year":"2020","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.ejrad.2025.112057_b0130","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00261-023-04143-1","article-title":"Diagnostic performance of MRI for residual or recurrent hepatocellular carcinoma after locoregional treatment according to contrast agent type: a systematic review and meta\u2011analysis","volume":"49","author":"Zhou","year":"2024","journal-title":"Abdom Radiol (NY)"},{"issue":"2","key":"10.1016\/j.ejrad.2025.112057_b0135","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00261-018-1775-x","article-title":"Diagnostic accuracy of MRI with extracellular vs. hepatobiliary contrast material for detection of residual hepatocellular carcinoma after locoregional treatment","volume":"44","author":"Rimola","year":"2019","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.ejrad.2025.112057_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2024.111829","article-title":"Current Status of the clinical role in Spanish interventional radiology: An online survey among the Spanish Society of Vascular and Interventional Radiology (SERVEI) members","volume":"181","author":"Garc\u00eda Jurado","year":"2024","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.ejrad.2025.112057_b0145","unstructured":"Chinese clinical practice guidelines for transarterial chemoembolization of hepatocellular carcinoma (2023 edition). Zhonghua Yi Xue Za Zhi, 2023, 103(34): 2674-2694. Doi: 10.3760\/cma.j.cn112137-20230630-01114."},{"issue":"3","key":"10.1016\/j.ejrad.2025.112057_b0150","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00270-024-03666-4","article-title":"Transarterial Chemoembolization with Epirubicin-Loaded Microspheres for Hepatocellular Carcinoma: A Prospective, Single-Arm, Multicenter, Phase 2 Study (STOPPER Trial)","volume":"47","author":"Zhu","year":"2024","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1","key":"10.1016\/j.ejrad.2025.112057_b0155","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41392-022-01235-0","article-title":"Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)","volume":"8","author":"Zhu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ejrad.2025.112057_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102622","volume":"72","author":"Jin","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"2","key":"10.1016\/j.ejrad.2025.112057_b0165","first-page":"401","article-title":"Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis","volume":"70","author":"Nathani","year":"2021","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.ejrad.2025.112057_b0170","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1038\/s41467-024-47420-3","article-title":"Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejrad.2025.112057_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2023.111086","article-title":"A radiomics signature associated with underlying gene expression pattern for the prediction of prognosis and treatment response in hepatocellular carcinoma","volume":"167","author":"Wang","year":"2023","journal-title":"Eur. J. Radiol."},{"key":"10.1016\/j.ejrad.2025.112057_b0180","article-title":"LI-RADS Nonradiation Treatment Response Algorithm Version 2024: Diagnostic Performance and Impact of Ancillary Features","author":"Zhou","year":"2024","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"10.1016\/j.ejrad.2025.112057_b0185","doi-asserted-by":"crossref","DOI":"10.1148\/rycan.259002","article-title":"Assessing HCC Response to Locoregional Therapies: Diagnostic Performance of LI-RADS Nonradiation Treatment Response Algorithm Version 2024 and the Role of Ancillary Features","volume":"7","author":"Rajeev","year":"2025","journal-title":"Radiol Imaging Cancer"}],"container-title":["European Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0720048X25001433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0720048X25001433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:00:29Z","timestamp":1778752829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0720048X25001433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":37,"alternative-id":["S0720048X25001433"],"URL":"https:\/\/doi.org\/10.1016\/j.ejrad.2025.112057","relation":{},"ISSN":["0720-048X"],"issn-type":[{"value":"0720-048X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A nationwide investigation on imaging follow-up after Locoregional therapy for hepatocellular carcinoma in China: Current practices and challenges","name":"articletitle","label":"Article Title"},{"value":"European Journal of Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejrad.2025.112057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112057"}}